Literature DB >> 12760890

Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Juliette Pavie1, Agnès Lefort, Marie-Cécile Ploy, Laurent Massias, Françoise Chau, Louis Garry, François Denis, Bruno Fantin.   

Abstract

The influence of reduced susceptibilities to glycopeptides on the activities of vancomycin and teicoplanin against an isogenic pair of clinical Staphylococcus aureus strains in experimental endocarditis was investigated. While vancomycin was similarly active against both strains, teicoplanin was approximately 100-fold less active against the resistant strain and selected for the emergence of more resistant subpopulations.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12760890      PMCID： PMC155861          DOI： 10.1128/AAC.47.6.2018-2021.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates.

Authors:  S Boyle-Vavra; S K Berke; J C Lee; R S Daum
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999.

Authors:  D J Diekema; M A Pfaller; F J Schmitz; J Smayevsky; J Bell; R N Jones; M Beach
Journal:  Clin Infect Dis       Date:  2001-05-15       Impact factor: 9.079

3.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

4.  Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam.

Authors:  M Backo; E Gaenger; A Burkart; Y L Chai; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

Review 5.  Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know.

Authors:  S K Fridkin
Journal:  Clin Infect Dis       Date:  2000-12-13       Impact factor: 9.079

6.  Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S M Seo; N J Dorman; S A Lerner
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

7.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

8.  Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.

Authors:  D N Gilbert; C A Wood; R C Kimbrough
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

9.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

10.  Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.

Authors:  B Fantin; R Leclercq; M Arthur; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191
View more
  6 in total

Review 1.  Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.

Authors:  B P Howden; P B Ward; P D R Johnson; P G P Charles; M L Grayson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

2.  Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.

Authors:  Mustafa Sacar; Suzan Sacar; Nural Cevahir; Gokhan Onem; Zafer Teke; Ali Asan; Huseyin Turgut; Fahri Adali; Ilknur Kaleli; Ibrahim Susam; Yalin Tolga Yaylali; Ahmet Baltalarli
Journal:  Tex Heart Inst J       Date:  2010

3.  Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.

Authors:  Nathalie Asseray; Cedric Jacqueline; Virginie Le Mabecque; Eric Batard; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  In vivo pharmacodynamic activity of the glycopeptide dalbavancin.

Authors:  David Andes; William A Craig
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

5.  Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.

Authors:  Agnès Lefort; Juliette Pavie; Louis Garry; Françoise Chau; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

6.  Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus, Taiwan.

Authors:  Jiun-Ling Wang; Sung-Pin Tseng; Po-Ren Hsueh; Keiichi Hiramatsu
Journal:  Emerg Infect Dis       Date:  2004-09       Impact factor: 6.883
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.